Earnings Releases·Nov 10, 2026, 4:46 PM ET

Azenta — Fiscal 2026 Earnings Summary

Fiscal 2026 revenue from continuing operations reached $622 million (up 5% YoY) with $27 million in free cash flow, though full-year diluted EPS from continuing operations declined to $(3.50) due to a $149 million non-cash goodwill impairment charge.
Full-year adjusted diluted EPS from continuing operations was $0.48 (down 6% YoY) and adjusted EBITDA was $58.3 million (down 12% YoY), while gross margin decreased 130 basis points to 44.2% amid unfavorable cost absorption and inventory reserves.
The company issued 2027 guidance projecting revenue between $648 million and $660 million (3%–5% organic growth) and an adjusted EBITDA margin expansion of 200–250 basis points, with free cash flow expected to improve approximately 25%.
Strategic capital deployment included the acquisition of SynPlexity Inc. for up to $25 million and agreements with Elegen Corp. for $32 million to $71 million to expand gene synthesis capabilities, alongside a share repurchase program authorizing up to $250 million through 2028.